{"organizations": [], "uuid": "d8c475f619d9050de22994ccb1a6356f9f44abb3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-dar-bioscience-enters-into-agreeme/brief-dar-bioscience-enters-into-agreement-to-license-sst-6007-a-potential-treatment-for-fsad-idUSASB0C568", "country": "US", "domain_rank": 408, "title": "BRIEF-Daré Bioscience Enters Into Agreement To License SST-6007, A Potential Treatment For FSAD", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-12T15:08:00.000+02:00", "replies_count": 0, "uuid": "d8c475f619d9050de22994ccb1a6356f9f44abb3"}, "author": "", "url": "https://www.reuters.com/article/brief-dar-bioscience-enters-into-agreeme/brief-dar-bioscience-enters-into-agreement-to-license-sst-6007-a-potential-treatment-for-fsad-idUSASB0C568", "ord_in_thread": 0, "title": "BRIEF-Daré Bioscience Enters Into Agreement To License SST-6007, A Potential Treatment For FSAD", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fsad reuters staff", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "bioscience inc", "sentiment": "none"}, {"name": "reuters) - dare bioscience inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 11 PM / in 8 minutes BRIEF-Daré Bioscience Enters Into Agreement To License SST-6007, A Potential Treatment For FSAD Reuters Staff 1 Min Read \nFeb 12 (Reuters) - Dare Bioscience Inc: \n* DARÉ BIOSCIENCE, INC. ENTERS INTO LICENSE AND COLLABORATION AGREEMENT FOR A PRODUCT WITH THE POTENTIAL TO RECEIVE THE FIRST FDA APPROVAL FOR FEMALE SEXUAL AROUSAL DISORDER \n* DARE BIOSCIENCE INC - ‍ENTERED INTO AN AGREEMENT TO LICENSE SST-6007​ \n* DARE BIOSCIENCE INC - ‍DARÉ ANTICIPATES COMMENCING A PHASE 2B CLINICAL TRIAL IN SECOND HALF OF 2018 FOR SST-6007​ Source text for Eikon:  ", "external_links": [], "published": "2018-02-12T15:08:00.000+02:00", "crawled": "2018-02-12T15:26:40.028+02:00", "highlightTitle": ""}